Literature DB >> 16077717

Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome.

A-C Santos1, C Lopes, J T Guimarães, H Barros.   

Abstract

INTRODUCTION: Traditional cardiovascular risk factors such as central obesity, high blood pressure and insulin resistance, all constituents of metabolic syndrome, have been associated with increased levels of C-reactive protein (CRP). Therefore, this marker of low-grade inflammation may play a major role in the pathogenesis of cardiovascular diseases. In this study, data from a representative sample of urban adults was used to evaluate the association between CRP and metabolic syndrome, accounting for the type and number of its constituents.
METHODS: Using random digit dialing, 1022 participants, aged 18-92 y, were selected. All participants completed a structured questionnaire comprising of information on social, demographic, behavioral and clinical aspects. Anthropometrics and blood pressure were recorded and a fasting blood sample collected. Metabolic syndrome was defined, according to the Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults, as the presence of three or more of the following characteristics: waist circumference greater than 102 cm in men and 88 cm in women; triglyceride levels > or = 150 mg/dl; high-density lipoprotein cholesterol levels < 40 mg/dl in men and < 50 mg/dl in women; blood pressure > or = 130/85 mm Hg; and serum glucose > or = 110 mg/dl. High-sensitivity CRP was assessed by immunonephelometric assay. After excluding 65 participants with CRP > or = 10 mg/l, 957 subjects (599 women and 358 men) remained for analysis. Geometric means were compared after adjustment for age, sex, alcohol consumption and smoking.
RESULTS: Higher mean levels of CRP (2.34 vs 1.36, P < 0.001) were observed when metabolic syndrome was present. Also, mean CRP levels were significantly higher in the presence of central obesity (2.45 vs 1.24, P < 0.001), high blood pressure (1.76 vs 1.12, P < 0.001), hypertriglyceridemia (2.17 vs 1.32, P < 0.001) and high fasting glucose (1.96 vs 1.46, P = 0.032). We found a significant increasing trend (P < 0.001) in mean levels of CRP as the number of features of metabolic syndrome increased. The major contributing features for high CRP levels were central obesity and high blood pressure.
CONCLUSIONS: Present data show that increasing severity of metabolic syndrome is associated with increasing CRP. Additionally, we found that central obesity and high blood pressure are the most important determinants of the low-grade chronic inflammation present in metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16077717     DOI: 10.1038/sj.ijo.0803035

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  41 in total

1.  C-reactive protein in adolescent twins: patterns and relationship to adiposity.

Authors:  Guoying Wang; Katherine Kaufer Christoffel; Wendy J Brickman; Xiumei Hong; Lester Arguelles; Shanchun Zhang; Binyan Wang; Zhiping Li; Houxun Xing; Gengfu Tang; Donald Zimmerman; Xiping Xu; Xiaobin Wang
Journal:  J Clin Endocrinol Metab       Date:  2011-08-10       Impact factor: 5.958

2.  Relationship of high-sensitive C-reactive protein with cardiovascular risk factors, clinical presentation and angiographic profile in patients with acute coronary syndrome: an Indian perspective.

Authors:  Sharad Gupta; Vitull K Gupta; Rupika Gupta; Sonia Arora; Varun Gupta
Journal:  Indian Heart J       Date:  2013-05-16

3.  High sensitivity C-reactive protein associated with different health predictors in middle-aged and oldest old Chinese.

Authors:  Yi Zhai; Xiao Ming Shi; Simon Michael Fitzgerald; Han Zhu Qian; Virginia B Kraus; Melanie Sereny; Perry Hu; Zhao Xue Yin; Jian Wei Xu; Yi Zeng
Journal:  Biomed Environ Sci       Date:  2012-06       Impact factor: 3.118

4.  Waist circumference and BMI in relation to serum high sensitivity C-reactive protein (hs-CRP) in Cuban Americans with and without type 2 diabetes.

Authors:  Fatma G Huffman; Suzanne Whisner; Gustavo G Zarini; Subrata Nath
Journal:  Int J Environ Res Public Health       Date:  2010-03-08       Impact factor: 3.390

Review 5.  Chronic inflammation in obesity and the metabolic syndrome.

Authors:  Rosário Monteiro; Isabel Azevedo
Journal:  Mediators Inflamm       Date:  2010-07-14       Impact factor: 4.711

6.  The influence of persistent pathogens on circulating levels of inflammatory markers: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis.

Authors:  Aydin Nazmi; Ana V Diez-Roux; Nancy S Jenny; Michael Y Tsai; Moyses Szklo; Allison E Aiello
Journal:  BMC Public Health       Date:  2010-11-17       Impact factor: 3.295

7.  High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population.

Authors:  Tomomi Kogiso; Yuriko Moriyoshi; Satoru Shimizu; Hikaru Nagahara; Keiko Shiratori
Journal:  J Gastroenterol       Date:  2009-03-07       Impact factor: 7.527

8.  Comparison of usefulness of body mass index versus metabolic risk factors in predicting 10-year risk of cardiovascular events in women.

Authors:  Yiqing Song; JoAnn E Manson; James B Meigs; Paul M Ridker; Julie E Buring; Simin Liu
Journal:  Am J Cardiol       Date:  2007-12-01       Impact factor: 2.778

9.  Depressive symptoms and metabolic syndrome: is inflammation the underlying link?

Authors:  Lucile Capuron; Shaoyong Su; Andrew H Miller; J Douglas Bremner; Jack Goldberg; Gerald J Vogt; Carisa Maisano; Linda Jones; Nancy V Murrah; Viola Vaccarino
Journal:  Biol Psychiatry       Date:  2008-07-02       Impact factor: 13.382

10.  Elevated C-reactive protein levels and metabolic syndrome in the elderly: The role of central obesity data from the InChianti study.

Authors:  Giovanni Zuliani; Stefano Volpato; Matteo Galvani; Alessandro Blè; Stefania Bandinelli; Anna Maria Corsi; Fulvio Lauretani; Marcello Maggio; Jack M Guralnik; Renato Fellin; Luigi Ferrucci
Journal:  Atherosclerosis       Date:  2008-08-12       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.